Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.33 |
| ▸ | DPYD | Q12882 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11433727 | 0.74 | TSHR (0.36) | PARP1DAOAURKAAURKBINCENP | |
| SCHEMBL4619120 | 0.71 | GRIN2D (0.33) | PARP1 | |
| SCHEMBL6902686 | 0.71 | ALDH1A1 (0.48) | CYP2A6ALDH1A1LMNABLMTDP1 | |
| SCHEMBL9774941 | 0.69 | HSD17B10 (0.39) | PARP1KDM4EHSD17B10 | |
| SCHEMBL2053929 | 0.68 | — | — | |
| SCHEMBL20571613 | 0.68 | — | — | |
| SCHEMBL12984655 | 0.68 | — | — | |
| SCHEMBL6902013 | 0.64 | MEN1 (0.35) | ALDH1A1TDP1 | |
| SCHEMBL1422273 | 0.64 | — | — | |
| SCHEMBL23674780 | 0.64 | PARP1 (0.32) | PARP1DPYDPKMDAOAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595273-B2 | Phosphonate conjugates and uses thereof | TRANSLATIONAL GENOMICS RES INST (US) | 2026-04-07 | — | — | US | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | UNITED STATES GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | UNITED STATES GOVERNMENT | 2022-04-21 | — | — | US | disclosed |
| EP-3911320-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | The Translational Genomics Research Institute (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150307-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150307-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2235001-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| CN-101535264-A | pyridone compound | BRISTOL MYERS SQUIBB CO (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2089364-A1 | PYRIDINONE COMPOUNDS | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | PARP1 4618/4885DPYD 4448/4885PKM 693/4885 |
| US-20220119425-A1 | PHOSPHONATE CONJUGATES AND USES THEREOF | ACP1, PTMS, RET | PARP1 2224/4885DPYD 1405/4885PKM 2495/4885 |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | RET, PTK2, ERBB2 | PARP1 3031/4885DPYD 1577/4885PKM 2287/4885 |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | MET, HGF, DCK | PARP1 1448/4885DPYD 618/4885PKM 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.